Advertisement
Advertisement
U.S. markets close in 1 hour 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9900+0.0009 (+0.09%)
As of 02:42PM EDT. Market open.
Advertisement

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees201

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO884.67kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer548.14kN/A1969
Mr. Gilead Raday MPhil, MScChief Operating Officer539.74kN/A1975
Mr. Adi FrishChief Corp. & Bus. Devel. Officer519.65kN/A1970
Mr. Rick D. ScruggsChief Commercial Officer, Pres of RedHill Biopharma Inc. & Director736.35kN/A1960
Dr. Mark L. Levitt M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Alexandra OkmianSr. Bus. Devel. & Investor Relations Mang.N/AN/AN/A
Ms. Valerie GraceffaVP of SalesN/AN/AN/A
Mr. Rob JacksonSr. VP of Sales & MarketingN/AN/AN/A
Ms. Michelle SnellingVP of HRN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement